Child’s Death Leads Beijing Health Officials To Suspend Use Of Sinovac’s Hepatitis A Vaccine
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - District Health Services Bureau officials in Beijing have suspended the use of one batch of Sinovac's inactivated hepatitis A vaccine, Healive, while investigating a possible adverse drug reaction and death of a two-year-old girl who was administered the vaccine